Asset Management One Co., Ltd. Nektar Therapeutics Transaction History

Asset Management One Co., Ltd.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$15.87 - $23.12 $1.47 Million - $2.14 Million	-92,567 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$16.91 - $36.27 $14,931 - $32,026	883 Added 0.96%	92,567 $1.69 Million
Q2 2019 Aug 14, 2019	BUY	$31.0 - $36.3 $320,137 - $374,870	10,327 Added 12.69%	91,684 $3.26 Million
Q1 2019 May 15, 2019	SELL	$31.58 - $46.35 $5.63 Million - $8.26 Million	-178,190 Reduced 68.65%	81,357 $2.73 Million
Q4 2018 Feb 13, 2019	BUY	$30.43 - $56.65 $35,329 - $65,770	1,161 Added 0.45%	259,547 $8.54 Million

Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $38,283 - $56,435	-824 Reduced 0.32%	258,386 $15.8 Million
Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $11.9 Million - $27 Million	258,175 Added 24944.44%	259,210 $12.6 Million
Q1 2018 May 14, 2018	BUY	$57.4 - $108.44 $59,409 - $112,235	1,035 New	1,035 $110,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Asset Management One Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Asset Management One Co., Ltd. with notifications on news.